Vetr Crowd Upgrades Bluebird After Trump Presser
On Wednesday, the Vetr crowd upgraded their rating for bluebird bio Inc (NASDAQ: BLUE), from 2.5 Stars (Sell) issued two days ago, to 3.5 Stars (Buy). Crowd sentiment for the stock is generally cautious, with 66 percent of Vetr user ratings bearish.
The gene therapy company experienced the same drop many biotech firms experienced in the wake of President-elect Donald Trump's first press conference following his election win in November. The sector saw an immediate selloff following the President-elect's comment about the cost of consumer drug prices.
Shares of bluebird bio fell over 5 percent to $64.70 immediately following the remark made around noon on January 11. The stock bounced back slightly as traders capitalized on the market's reaction. The stock still finished the day down at $65.05.
Currently, the Vetr crowd's average target price for the stock is up at $69.48, which is well below the average analyst target price of $88.77. Less than 2 percent of Vetr users are holding BLUE in their watch lists.
Latest Ratings for BLUE
|Feb 2017||Maxim Group||Downgrades||Buy||Hold|
|Feb 2017||Roth Capital||Downgrades||Buy||Neutral|
|Nov 2016||BMO Capital||Initiates Coverage On||Market Perform|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.